Richard Sola, MD
Interventional Cardiology · Safety Harbor, FLNPI 1245228626
Payments from drug & device makers
Across 564 payments — averaging $458.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$74K
- Novo Nordisk AS$66K
- Surmodics, Inc.$42K
- Angiodynamics, Inc.$22K
- Atrium Medical Corporation$21K
- Cardiovascular Systems Inc.$20K
- plus $13K from 24 others
What the payments were for
- Travel & lodging$7,43418%
- Food & beverage$11,70828%
- Education$770%
- Other$22,25054%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 36 | $73,888 |
| Novo Nordisk AS | 185 | $66,079 |
| Surmodics, Inc. | 44 | $42,327 |
| Angiodynamics, Inc. | 7 | $22,350 |
| Atrium Medical Corporation | 14 | $20,750 |
| Cardiovascular Systems Inc. | 35 | $20,085 |
| Medtronic(2 entities) | 77 | $6,729 |
| Shockwave Medical, Inc | 26 | $1,561 |
| W. L. Gore & Associates, Inc. | 22 | $916 |
| Zimmer Biomet | 8 | $805 |
| Boston Scientific | 20 | $665 |
| Abbott | 9 | $593 |
| Amgen | 19 | $307 |
| Endologix LLC | 5 | $301 |
| Cook Medical LLC | 10 | $224 |
| Johnson & Johnson(2 entities) | 5 | $184 |
| AstraZeneca | 10 | $128 |
| Astellas Pharma US Inc | 1 | $77 |
| Pfizer | 5 | $75 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $70 |
| Novartis | 4 | $70 |
| Sanofi-aventis U.S. LLC | 3 | $67 |
| E.r. Squibb & Sons, L.L.C. | 5 | $63 |
| Abiomed | 2 | $61 |
| Amarin Pharma, Inc. | 2 | $40 |
| Novo Nordisk | 1 | $25 |
| Terumo Medical Corporation | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$21,917
- IN.PACT Admiral$4,150
- Indigo$3,956
- Peripheral Orbital Atherectomy System$1,246
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$978
- Endurant$789
- RibFix Blu$591
- VenaCure 1470 Pro$333
- GORE EXCLUDER AAA Endoprosthesis$295
- Supera peripheral stent system$260
- Coronary Orbital Atherectomy System$242
- Shockwave Intravascular Lithotripsy (IVL) System with the Shockwave E8 Peripher$159
- Indigo System$150
- Vascular Lithotripsy$147
- GORE TAG Thoracic Endoprosthesis$136
- Diamondback Coronary$127
- ELUVIA$127
- Ovation$123
- MATRIXRIB$119
- HawkOne$114
How this compares
$258,500 in reported general payments places this provider in the 90th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 107 | $155,005 |
| Repatha SureclickEvolocumab | 48 | $38,554 |
| XareltoRivaroxaban | 33 | $37,922 |
| BrilintaTicagrelor | 32 | $16,489 |
| VascepaIcosapent Ethyl | 12 | $2,931 |
| Nebivolol Hcl | 35 | $2,894 |
| Ranolazine ErRanolazine | 13 | $2,532 |
| ClopidogrelClopidogrel Bisulfate | 247 | $2,187 |
| Irbesartan | 128 | $1,899 |
| Rosuvastatin Calcium | 204 | $1,784 |
| Potassium Chloride | 56 | $1,700 |
| Ezetimibe | 106 | $1,676 |
| Atorvastatin Calcium | 127 | $1,637 |
| Metoprolol Succinate | 153 | $1,566 |
| Amlodipine Besylate | 214 | $1,161 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $75 | $155,005107 claims |
| Johnson & JohnsonXarelto | $184 | $37,92233 claims |
| AstraZenecaBrilinta | $128 | $16,48932 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Safety Harbor
- Parag PatelSafety Harbor$950K
- Lang LinSafety Harbor$544K
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Roberto CubedduNaples$2M
- Arthur LeeGainesville$2M
- Ruby SatpathyJacksonville$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.